Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Obesity Reports
Published in: Current Obesity Reports 2/2016

01-06-2016 | Obesity Treatment (CM Apovian, Section Editor)

New Dietary Supplements for Obesity: What We Currently Know

Authors: Alejandro Ríos-Hoyo, Gabriela Gutiérrez-Salmeán

Published in: Current Obesity Reports | Issue 2/2016

Login to get access

Abstract

Obesity and its associated cardiometabolic alterations currently are considered an epidemic; thus, their treatment is of major importance. The cornerstone for such treatment involves therapeutic lifestyle changes; however, the vast majority of cases fail and/or significant weight loss is maintained only in the short term because of lack of compliance. The popularity of dietary supplements for weight management has increased, and a wide variety of these products are available over the counter. However, the existing scientific evidence is insufficient to recommend their safe use. Hence, the purpose of this article is to review the clinical effects, proposed mechanism of action, and safety profile of some of the new dietary supplements, including white bean extract, Garcinia cambogia, bitter orange, Hoodia gordonii, forskolin, green coffee, glucomannan, β-glucans, chitosan, guar gum, and raspberry ketones.
Literature
1.
2.
3.
4.•
Geller A, Shehab N, Weidle N, Lovegrove M, Wolpert B, Timbo B, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373:1531–40. This reference is of importance due to its novelty and wide approach to the subject of interest. This provides an overview that allows non-experts to begin familiarizing with the subject.
5.
Stohs SJ, Preuss HG, Shara M. The safety of Citrus aurantium (bitter orange) and its primary protoalkaloid p‐synephrine. Phytother Res. 2011;25:1421–8.CrossRefPubMed
6.
Fugh-Berman A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp Biol Med. 2004;229:698–704.
7.
Allison DB, Cutter G, Poehlman ET, Moore DR, Barnes S. Exactly which synephrine alkaloids does Citrus aurantium (bitter orange) contain? Int J Obes (Lond). 2005;29:443–6.CrossRef
8.
Haaz S, Fontaine KR, Cutter G, Limdi N, Perumean-Chaney S, Allison DB. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Rev. 2006;7:79–88.CrossRefPubMed
9.
Colker CM, Kalman DS, Torina GC, Perlis T, Street C. Effects of Citrus aurantium extract, caffeine, and St. John’s Wort on body fat loss, lipid levels, and mood states in overweight healthy adults. Curr Ther Res. 1999;60:145–53.CrossRef
10.
Kalman DS, Colker CM, Shi QH, Swain MA. Effects of a weight-loss aid in healthy overweight adults: double-blind, placebo-controlled clinical trial. Curr Ther Res Exp. 2000;61:199–205.CrossRef
11.
Stohs SJ, Preuss HG, Keith SC, Keith PL, Miller H, Kaats GR. Effects of p-synephrine alone and in combination with selected bioflavonoids on resting metabolism, blood pressure, heart rate and self-reported mood changes. Int J Med Sci. 2011;8:295–301.CrossRefPubMedPubMedCentral
12.
Kim G-S, Park HJ, Woo J-H, Kim M-K, Koh P-O, Min W, et al. Citrus aurantium flavonoids inhibit adipogenesis through the Akt signaling pathway in 3T3-L1 cells. BMC Complement Altern Med [Internet]. 2012;12:31.CrossRef
13.
Bent S, Padula A, Neuhaus J. Safety and efficacy of Citrus aurantium for weight loss. Am J Cardiol. 2004;94:1359–61.CrossRefPubMed
14.
Kaats GR, Miller H, Preuss HG, Stohs SJ. A 60day double-blind, placebo-controlled safety study involving Citrus aurantium (bitter orange) extract. Food Chem Toxicol. 2013;55:358–62.CrossRefPubMed
15.
Stohs SJ. Assessment of the adverse event reports associated with Citrus aurantium (bitter orange) from April 2004 to October 2009. J Funct Foods. 2010;2:235–8.CrossRef
16.
Russell PJ, Swindells C. Chemical characterisation of Hoodia gordonii extract. Food Chem Toxicol. 2012;50(S):6–13.CrossRef
17.
Van Heerden FR. Hoodia gordonii: a natural appetite suppressant. J Ethnopharmacol. 2008;119:434–7.CrossRefPubMed
18.
19.
MacLean DB, Luo LG. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside. Brain Res. 2004;1020:1–11.CrossRefPubMed
20.
Le Nevé B, Foltz M, Daniel H, Gouka R. The steroid glycoside H.g.-12 from Hoodia gordonii activates the human bitter receptor TAS2R14 and induces CCK release from HuTu-80 cells. Am J Physiol Gastrointest Liver Physiol. 2010;299:G1368–75.CrossRefPubMed
21.
Blom WAM, Abrahamse SL, Bradford R, Duchateau GSMJE, Theis W, Orsi A, et al. Effects of 15-d repeated consumption of Hoodia gordonii purified extract on safety, ad libitum energy intake, and body weight in healthy, overweight women: a randomized controlled trial. Am J Clin Nutr. 2011;94:1171–81.CrossRefPubMed
22.
Yamoneka J, Malumba P, Blecker C, Gindo M, Richard G, Fauconnier M-L, et al. Physicochemical properties and thermal behaviour of African wild mango (Irvingia gabonensis) seed fat. LWT - Food Sci Technol. 2015;64:989–96.CrossRef
23.
Ribeiro SMR, Barbosa LCA, Queiroz JH, Knödler M, Schieber A. Phenolic compounds and antioxidant capacity of Brazilian mango (Mangifera indica L.) varieties. Food Chem. 2008;110:620–6.CrossRef
24.
Arogba SS. Phenolics, antiradical assay and cytotoxicity of processed mango (Mangifera indica) and bush mango (Irvingia gabonensis) kernels. Niger Food J. 2014;32:62–72.CrossRef
25.
Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids Health Dis. 2008;7:44.CrossRefPubMedPubMedCentral
26.
Ngondi JL, Oben JE, Minka SR. The effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in Cameroon. Lipids Health Dis. 2005;4:12.CrossRefPubMedPubMedCentral
27.
Oben JE, Ngondi JL, Momo CN, Agbor GA, Sobgui CSM. The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids Health Dis. 2008;7:12.CrossRefPubMedPubMedCentral
28.
Onakpoya I, Davies L, Posadzki P, Ernst E. The efficacy of Irvingia gabonensis supplementation in the management of overweight and obesity: a systematic review of randomized controlled trials. J Diet Suppl. 2013;10:29–38.CrossRefPubMed
29.
Farah A, Donangelo CM. Phenolic compounds in coffee. Brazilian J Plant Physiol. 2006;18:23–36.CrossRef
30.
31.•
Mullin G. Supplements for weight loss: hype or help for obesity? Part II. The inside scoop on green coffee bean extract. Nutr Clin Pract. 2015;30:311–2. This reference is of importance due to its novelty and wide approach to the subject of interest. This provides an overview that allows non-experts to begin familiarizing with the subject.
32.
Flanagan J, Bily A, Rolland Y, Roller M. Lipolytic activity of Svetol®, a decaffeinated green coffee bean extract. Phytother Res. 2014;28:946–8.CrossRefPubMed
33.
Shimoda H, Seki E, Aitani M. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. BMC Complement Altern Med. 2006;6:9.CrossRefPubMedPubMedCentral
34.
Cho AS, Jeon SM, Kim MJ, Yeo J, Seo KI, Choi MS, et al. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem Toxicol. 2010;48:937–43.CrossRefPubMed
35.
Onakpoya I, Terry R, Ernst E. The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. Gastroenterol Res Pract. 2011;2011:1–6.CrossRef
36.
Kavitha C, Rajamani K, Vadivel E. Coleus forskohlii: a comprehensive review on morphology, phytochemistry and pharmacological aspects. J Med Plants Res. 2010;4:278–85.
37.
Insel PA, Ostrom RS. Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell Mol Neurobiol. 2003;23:305–14.CrossRefPubMed
38.
Godard MP, Johnson BA, Richmond SR. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obes Res. 2005;13:1335–43.CrossRefPubMed
39.
Henderson S, Magu B, Rasmussen C, Lancaster S, Kerksick C, Smith P, et al. Effects of coleus forskohlii supplementation on body composition and hematological profiles in mildly overweight women. J Int Soc Sports Nutr. 2005;2:54–62.CrossRefPubMedPubMedCentral
40.
Peng J, Yuan JP, Wu CF, Wang JH. Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. Mar Drugs. 2011;9:1806–28.CrossRefPubMedPubMedCentral
41.
Hu X, Li Y, Li C, Fu Y, Cai F, Chen Q, et al. Combination of fucoxanthin and conjugated linoleic acid attenuates body weight gain and improves lipid metabolism in high-fat diet-induced obese rats. Arch Biochem Biophys. 2012;519:59–65.CrossRefPubMed
42.
Beppu F, Hosokawa M, Niwano Y, Miyashita K. Effects of dietary fucoxanthin on cholesterol metabolism in diabetic/obese KK-Ay mice. Lipids Health Dis. 2012;11:112.CrossRefPubMedPubMedCentral
43.
Wu M, Singh SB, Wang J, Chung CC, Salituro G, Karanam BV, et al. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc Natl Acad Sci. 2011;108:5378–83.CrossRefPubMedPubMedCentral
44.
45.
Kang S-I, Ko H-C, Shin H-S, Kim H-M, Hong Y-S, Lee N-H, et al. Fucoxanthin exerts differing effects on 3T3-L1 cells according to differentiation stage and inhibits glucose uptake in mature adipocytes. Biochem Biophys Res Commun. 2011;409:769–74.CrossRefPubMed
46.
47.
Maeda H, Hosokawa M, Sashima T, Funayama K, Miyashita K. Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun. 2005;332:392–7.CrossRefPubMed
48.
Buras E. The effects of XanthigenTM supplementation on body composition, serum markers of the metabolic syndrome, and hepaptic enzyme levels in an obese population. Honors Theses. The University of Southern Mississippi; 2012.
49.
Abidov M, Ramazanov Z, Seifulla R, Grachev S. The effects of XanthigenTM in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab. 2010;12:72–81.CrossRefPubMed
50.
Bredsdorff L, Wedebye EB, Nikolov NG, Hallas-Møller T, Pilegaard K. Raspberry ketone in food supplements—high intake, few toxicity data—a cause for safety concern? Regul Toxicol Pharmacol. 2015;73:196–200.CrossRefPubMed
51.
Park KS. Raspberry ketone increases both lipolysis and fatty acid oxidation in 3T3-L1 adipocytes. Planta Med. 2010;76:1654–8.CrossRefPubMed
52.•
Park KS. Raspberry ketone, a naturally occurring phenolic compound, inhibits adipogenic and lipogenic gene expression in 3T3-L1 adipocytes. Pharm Biol. 2015;53:870–5. This reference is of importance due to its novelty and wide approach to the subject of interest. This provides an overview that allows non-experts to begin familiarizing with the subject.
53.
Morimoto C, Satoh Y, Hara M, Inoue S, Tsujita T, Okuda H. Anti-obese action of raspberry ketone. Life Sci. 2005;77:194–204.CrossRefPubMed
54.
Alonso-Sande M, Teijeiro-Osorio D, Remuñán-López C, Alonso MJ. Glucomannan, a promising polysaccharide for biopharmaceutical purposes. Eur J Pharm Biopharm. 2009;72:453–62.CrossRefPubMed
55.
Davé V, McCarthy S. Review of konjac glucomannan. J Polym Environ. 1997;5:237–41.
56.
Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med. 2005;11:30–4.PubMed
57.
Keithley JK, Swanson B, Mikolaitis SL, DeMeo M, Zeller JM, Fogg L, et al. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. J Obes. 2013;2013:610908.CrossRefPubMedPubMedCentral
58.
Onakpoya I, Posadzki P, Ernst E. The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr. 2014;33:70–8.CrossRefPubMed
59.
Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008;88:1167–75.PubMed
60.
Cloetens L, Ulmius M, Johansson-Persson A, Åkesson B, Önning G. Role of dietary beta-glucans in the prevention of the metabolic syndrome. Nutr Rev. 2012;70:444–58.CrossRefPubMed
61.
El Khoury D, Cuda C, Luhovyy BL, Anderson GH. Beta glucan: health benefits in obesity and metabolic syndrome. J Nutr Metab. 2012;2012:851362.PubMedPubMedCentral
62.
Synytsya A, Míčková K, Synytsya A, Jablonský I, Spěváček J, Erban V, et al. Glucans from fruit bodies of cultivated mushrooms Pleurotus ostreatus and Pleurotus eryngii: structure and potential prebiotic activity. Carbohydr Polym. 2009;76:548–56.CrossRef
63.
Maki KC, Galant R, Samuel P, Tesser J, Witchger MS, Ribaya-Mercado JD, et al. Effects of consuming foods containing oat beta-glucan on blood pressure, carbohydrate metabolism and biomarkers of oxidative stress in men and women with elevated blood pressure. Eur J Clin Nutr. 2007;61:786–95.CrossRefPubMed
64.
Queenan KM, Stewart ML, Smith KN, Thomas W, Fulcher RG, Slavin JL. Concentrated oat beta-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. Nutr J. 2007;6:6.CrossRefPubMedPubMedCentral
65.
Davy BM, Melby CL, Beske SD, Ho RC, Davrath LR, Davy KP. Oat consumption does not affect resting casual and ambulatory 24-h arterial blood pressure in men with high-normal blood pressure to stage I hypertension. J Nutr. 2002;132:394–8.PubMed
66.
Kabir M, Oppert J-M, Vidal H, Bruzzo F, Fiquet C, Wursch P, et al. Four-week low-glycemic index breakfast with a modest amount of soluble fibers in type 2 diabetic men. Metabolism. 2002;51:819–26.CrossRefPubMed
67.
Lyly M, Liukkonen KH, Salmenkallio-Marttila M, Karhunen L, Poutanen K, Lähteenmäki L. Fibre in beverages can enhance perceived satiety. Eur J Nutr. 2009;48:251–8.CrossRefPubMed
68.
Lyly M, Ohls N, Lähteenmäki L, Salmenkallio-Marttila M, Liukkonen K-H, Karhunen L, et al. The effect of fibre amount, energy level and viscosity of beverages containing oat fibre supplement on perceived satiety. Food Nutr Res. 2010;54:1–8.CrossRef
69.
Willis HJ, Eldridge AL, Beiseigel J, Thomas W, Slavin JL. Greater satiety response with resistant starch and corn bran in human subjects. Nutr Res. 2009;29:100–5.CrossRefPubMed
70.
Kim H, Behall KM, Vinyard B, Conway JM. Short-term satiety and glycemic response after consumption of whole grains with various amounts of beta-glucan. Cereal Foods World. 2006;51:29–33.
71.
Peters HPF, Boers HM, Haddeman E, Melnikov SM, Qvyjt F. No effect of added ß-glucan or of fructooligosaccharide on appetite or energy intake. Am J Clin Nutr. 2009;89:58–63.CrossRefPubMed
72.
73.
Pasman WJ, Westerterp-Plantenga MS, Muls E, Vansant G, van Ree J, Saris WH. The effectiveness of long-term fibre supplementation on weight maintenance in weight-reduced women. Int J Obes Relat Metab Disord. 1997;21:548–55.CrossRefPubMed
74.
Pittler MH, Ernst E. Guar gum for body weight reduction: meta-analysis of randomized trials. Am J Med. 2001;110:724–30.CrossRefPubMed
75.
Dall’Alba V, Silva FM, Antonio JP, Steemburgo T, Royer CP, Almeida JC, et al. Improvement of the metabolic syndrome profile by soluble fibre—guar gum—in patients with type 2 diabetes: a randomised clinical trial. Br J Nutr. 2013;110:1601–10.CrossRefPubMed
76.
Mattes RD. Effects of a combination fiber system on appetite and energy intake in overweight humans. Physiol Behav. 2007;90:705–11.CrossRefPubMed
77.
Saper RB, Eisenberg DM, Phillips RS. Common dietary supplements for weight loss. Am Fam Physician. 2004;70:1731–8.PubMed
78.
Van Bennekum AM, Nguyen DV, Schulthess G, Hauser H, Phillips MC. Mechanisms of cholesterol-lowering effects of dietary insoluble fibres: relationships with intestinal and hepatic cholesterol parameters. Br J Nutr. 2005;94:331–7.CrossRefPubMed
79.
Ernst E, Pittler MH. Chitosan as a treatment for body weight reduction? A meta-analysis. Perfusion. 1998;11:461–5.
80.
Pereira A, Guedes AD, Verreschi ITN, Santos RD, Martinez TLR. Obesity and its association with other cardiovascular risk factors in school children in Itapetininga. Brazil Arq Bras Cardiol. 2009;93:253–60.PubMed
81.
Schiller RN, Barrager E, Schauss AG, Nichols EJ. A randomized, double-blind, placebo-controlled study examining the effects of a rapidly soluble chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals. JANA. 2001;4:42–9.
82.
Mhurchu CN, Poppitt SD, McGill A-T, Leahy FE, Bennett DA, Lin RB, et al. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord. 2004;28:1149–56.CrossRefPubMed
83.
Guerciolini R, Radu-Radulescu L, Boldrin M, Dallas J, Moore R. Comparative evaluation of fecal fat excretion induced by orlistat and chitosan. Obes Res. 2001;9:364–7.CrossRefPubMed
84.
Vinson J, Kharrat HA, Shuta D. Investigation of an amylase inhibitor on human glucose absorption after starch consumption. Open Nutraceuticals J. 2009;2009:88–91.CrossRef
85.
Celleno L, Tolaini MV, D’Amore A, Perricone NV, Preuss HG. A Dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. Int J Med Sci. 2007;4:45–52.CrossRefPubMedPubMedCentral
86.
Onakpoya I, Aldaas S, Terry R, Ernst E. The efficacy of Phaseolus vulgaris as a weight-loss supplement: a systematic review and meta-analysis of randomised clinical trials. Br J Nutr. 2011;106:196–202.CrossRefPubMed
87.
Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998;280:1596–600.CrossRefPubMed
88.
Astell KJ, Mathai ML, Su XQ. Plant extracts with appetite suppressing properties for body weight control: a systematic review of double blind randomized controlled clinical trials. Complement Ther Med. 2013;21:407–16.CrossRefPubMed
89.
De Lira-Garcia C, Souto-Gallardo M, Bacardi-Gascon M, Jimenez-Cruz A. A systematic review of the effectiveness of alternative weight-loss products’ ingredients. Rev Salud Publica (Bogota). 2008;10:818–30.CrossRef
90.
Kim K-Y, Lee HN, Kim YJ, Park T. Garcinia cambogia extract ameliorates visceral adiposity in C57BL/6J mice fed on a high-fat diet. Biosci Biotechnol Biochem. 2008;72:1772–80.CrossRefPubMed
91.
Kim YJ, Choi MS, Park YB, Kim SR, Lee MK, Jung UJ. Garcinia cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. World J Gastroenterol. 2013;19:4689–701.CrossRefPubMedPubMedCentral
92.
93.
Márquez F, Babio N, Bulló M, Salas-Salvadó J. Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans. Crit Rev Food Sci Nutr. 2012;52:585–94.CrossRefPubMed
94.
Semwal RB, Semwal DK, Vermaak I, Viljoen A. A comprehensive scientific overview of Garcinia cambogia. Fitoterapia. 2015;102:134–48.CrossRefPubMed
95.
Pittler M, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr. 2004;79:529–36.PubMed
Metadata
Title
New Dietary Supplements for Obesity: What We Currently Know
Authors
Alejandro Ríos-Hoyo
Gabriela Gutiérrez-Salmeán
Publication date
01-06-2016
Publisher
Springer US
Published in
Current Obesity Reports / Issue 2/2016
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-016-0214-y

Other articles of this Issue 2/2016

Current Obesity Reports 2/2016 Go to the issue

Obesity Prevention (A Must, Section Editor)

Parent–Child Interaction, Self-Regulation, and Obesity Prevention in Early Childhood

Obesity Prevention (A Must, Section Editor)

Obesity Prevention in Older Adults

Obesity Treatment (CM Apovian, Section Editor)

Macronutrient Content of the Diet: What Do We Know About Energy Balance and Weight Maintenance?

Obesity Treatment (CM Apovian, Section Editor)

Obesity as a Disease: Current Policies and Implications for the Future

Obesity Treatment (CM Apovian, Section Editor)

Adipose Tissue and Energy Expenditure: Central and Peripheral Neural Activation Pathways

Obesity Prevention (A Must, Section Editor)

The School Food Environment and Obesity Prevention: Progress Over the Last Decade
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits